Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 211Triple Negative Breast Neoplasms 32Stomach Neoplasms 32Inflammatory Breast Neoplasms 21Esophageal Neoplasms 16Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Lymphoma 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2

Interventions

Cytarabine 86fludarabine phosphate 85Peripheral Blood Stem Cell Transplantation 76Cyclophosphamide 69Busulfan 63Mycophenolic Acid 51Tacrolimus 48Cyclosporine 48Etoposide 43Whole-Body Irradiation 42Antilymphocyte Serum 40Methotrexate 39Filgrastim 39Flow Cytometry 30Radiotherapy 29Melphalan 24Mitoxantrone 23Daunorubicin 23Idarubicin 21Cord Blood Stem Cell Transplantation 19Polymerase Chain Reaction 17Methylprednisolone 17Gene Expression Profiling 17sargramostim 15Granulocyte Colony-Stimulating Factor 15Clofarabine 15Transplantation 14Decitabine 14Gemtuzumab 13aldesleukin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Abnormalities × Epirubicin × Clear all
NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Suspended
59 enrolled
Lymphoid

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡